GBA1 and Gaucher disease: As well, the approval of recombinant β-glucocerebrosidase produced in carrot cells for the treatment of Gaucher’s disease (a rare disease associated with mutations in the GBA1 gene that may be a risk factor for NDD onset [164]) by the FDA [113,135] gives us hope that the progress of these immunotherapeutic strategies will definitely affect the management of NDDs in a positive manner.